Every 8-K that Globalink Invest (GLLI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GLLI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GLLI filings page.
Globalink Investment Inc. reported that its stockholders approved a business combination with Alps Life Sciences Inc. and related corporate changes at a special meeting on October 7, 2025. Investors unanimously backed the redomestication merger, under which Globalink will merge into Alps Global Holding Pubco, and the acquisition merger, in which a PubCo subsidiary will merge with Alps so that Alps becomes a wholly owned subsidiary of PubCo.
Stockholders also approved an amendment to Globalink’s charter to remove the requirement that any initial business combination leave the company with at least $5,000,001 of net tangible assets. In connection with the vote, holders of 59,966 public shares chose to redeem their shares for cash, leaving 12,635 public shares outstanding.
Globalink Investment Inc. extended the deadline to complete its initial business combination by one month. On October 4, 2025, the company deposited an Extension Payment of $0.15 per public share, totaling $10,890.15, into its trust account for public stockholders. This payment moves the termination date for completing a merger or similar transaction from October 9, 2025 to November 9, 2025.
This is the company’s twenty-eighth extension since its initial public offering on December 9, 2021, and the fifth of up to six extensions currently permitted under its Amended and Restated Certificate of Incorporation. The company also issued a press release describing the decision, which is filed as an exhibit.
Globalink Investment Inc. entered into a Third Amendment to its merger agreement with Alps Life Sciences Inc. on September 27, 2025. The amendment allows Dr. Tham Seng Kong, in his personal capacity, to contribute all escrow shares from his personal entitlement of merger consideration shares, changing how a portion of his stock-based consideration is held in escrow.
The amendment also extends the deadline for obtaining the written consent of Alps Holdco shareholders, giving more time to secure formal approval for the business combination. The planned transaction will be completed through Alps Global Holding Pubco, which has filed a Form F-4 registration statement that includes a proxy statement/prospectus for Globalink stockholders.